Solid Tumors Expressing CEA
Showing 1 - 25 of >10,000
Carcinoma Trial (Intravenous infusion anti-CEA-CAR-T cell)
Not yet recruiting
- Carcinoma
- Intravenous infusion anti-CEA-CAR-T cell
- (no location specified)
Aug 22, 2023
Gastric Cancer, Colon Cancer, Rectal Cancer Trial in Wuhu (CEA-targeted CAR-T cells)
Recruiting
- Gastric Cancer
- +7 more
- CEA-targeted CAR-T cells
-
Wuhu, Anhui, ChinaThe First Affiliated Hospital of Wannan Medical College
Nov 9, 2023
Gastric Cancer, Colon Cancer, Rectal Cancer Trial in Taiyuan (CEA-targeted CAR-T cells)
Recruiting
- Gastric Cancer
- +6 more
- CEA-targeted CAR-T cells
-
Taiyuan, Shanxi, China
- +1 more
Aug 24, 2023
Gastric Cancer, Colon Cancer, Pancreas Cancer Trial in Nanchang (CEA CAR-T cells)
Recruiting
- Gastric Cancer
- +6 more
- CEA CAR-T cells
-
Nanchang, Jiangxi, ChinaThe First Affiliated Hospital of Nanchang University
Aug 23, 2023
Colorectal Cancer, Esophagus Cancer, Gastric Cancer Trial in Hangzhou (CEA-targeted CAR-T cells)
Recruiting
- Colorectal Cancer
- +6 more
- CEA-targeted CAR-T cells
-
Hangzhou, Zhejiang, China
- +1 more
Sep 18, 2023
Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer Trial in United States (A2B530, xT-Onco with HLA-LOH Assay)
Not yet recruiting
- Solid Tumor, Adult
- +15 more
- A2B530
- xT-Onco with HLA-LOH Assay
-
Duarte, California
- +6 more
Feb 10, 2023
Gastric Cancer, Colon Cancer, Rectal Cancer Trial in Henan (CEA-targeted CAR-T cells)
Recruiting
- Gastric Cancer
- +4 more
- CEA-targeted CAR-T cells
-
Henan, ChinaHe'nan Cancer Hospital
Sep 9, 2022
Her2-positive/Low-expression Urinary and Digestive Tract Tumors Trial in Beijing (BL-M07D1)
Not yet recruiting
- Her2-positive/Low-expression Urinary and Digestive Tract Tumors
-
Beijing, Beijing, ChinaCancer Hospital, Chinese Academy of Medical Sciences
Sep 8, 2023
Colorectal Cancer, Esophageal Cancer, Stomach Cancer Trial in Jinan (CEA CAR-T cells)
Recruiting
- Colorectal Cancer
- +5 more
- CEA CAR-T cells
-
Jinan, Shandong, ChinaThe Second People's Hospital of Shandong Province
Jul 19, 2022
Advanced or Metastatic Solid Tumors Trial in Beijing (CD40 ligand expressing MSLN-CAR T cells, Albumin-bound paclitaxel,
Recruiting
- Advanced or Metastatic Solid Tumors
- CD40 ligand expressing MSLN-CAR T cells
- +2 more
-
Beijing, Beijing, ChinaKaichao Feng
Jan 19, 2023
Advanced Solid Tumor Trial in Dallas (TCRT-ESO-A2)
Withdrawn
- Advanced Solid Tumor
- TCRT-ESO-A2
- (no location specified)
Aug 31, 2022
Solid Tumor, Adult, Advanced Solid Tumor, Advanced Renal Cell Carcinoma Trial in Australia (89Zr-TLX250, 177Lu-TLX250 and
Recruiting
- Solid Tumor, Adult
- +2 more
- 89Zr-TLX250
- 177Lu-TLX250 and Peposertib
-
North Ryde, New South Wales, Australia
- +4 more
May 22, 2023
Colorectal Cancer, Esophageal Cancer, Stomach Cancer Trial in Hangzhou (CEA CAR-T cells)
Recruiting
- Colorectal Cancer
- +5 more
- CEA CAR-T cells
-
Hangzhou, Zhejiang, ChinaFirst affiliated hospital, Zhejiang University
May 30, 2022
HER2+ Advanced Breast Cancer, Other Solid Tumors Trial (ADCC-R-Epo-R T-cells + Trastuzumab, Erythropoietin beta, Fludarabine and
Not yet recruiting
- HER2+ Advanced Breast Cancer
- Other Solid Tumors
- ADCC-R-Epo-R T-cells + Trastuzumab
- +2 more
- (no location specified)
Aug 31, 2023
HER2-expressing Advanced Solid Tumors Trial (SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor
Not yet recruiting
- HER2-expressing Advanced Solid Tumors
- SHR-A1811 combined with Pyrotinib.
- SHR-A1811 combined with other antitumor therapies
- (no location specified)
Aug 28, 2023
Advanced Solid Tumor Trial (SHR-4602 for injection)
Not yet recruiting
- Advanced Solid Tumor
- SHR-4602 for injection
- (no location specified)
Apr 6, 2023
Locally Advanced or Metastatic Solid Tumors Trial in Beijing (MSC-IFNa, Nab paclitaxel, Cyclophosphamide)
Recruiting
- Locally Advanced or Metastatic Solid Tumors
- MSC-IFNα
- +3 more
-
Beijing, ChinaDepartment of Biotherapeutic, Chinese PLA General Hospital
Jan 29, 2023
Solid Tumors Trial (TCR-T cells, Fludarabine, Cyclophosphamide Capsules)
Not yet recruiting
- Solid Tumors
- TCR-T cells
- +4 more
- (no location specified)
Dec 12, 2022
HER2 Expressing or Mutated Advanced Malignant Solid Tumors Trial in China (GQ1005)
Recruiting
- HER2 Expressing or Mutated Advanced Malignant Solid Tumors
-
Beijing, Beijing, China
- +19 more
Nov 23, 2023
HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification Trial in San Antonio, Fairfax (ORM-5029)
Not yet recruiting
- HER2-positive Breast Cancer
- +3 more
-
San Antonio, Texas
- +1 more
Aug 22, 2022
Advanced Solid Tumors Trial in Shanghai, Chengdu (SHR-A1811, Fluzoparib Capsule)
Enrolling by invitation
- Advanced Solid Tumors
- SHR-A1811
- Fluzoparib Capsule
-
Shanghai, Shanghai, China
- +1 more
Jun 28, 2022
Sarcoma, Osteosarcoma, Neuroblastoma Trial run by the NCI (Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide)
Completed
- Sarcoma
- +3 more
- Anti-GD2-CAR engineered T cells
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 31, 2023
Solid Tumor Trial in Belgium, Netherlands, United Kingdom (SYD985 + Niraparib)
Active, not recruiting
- Solid Tumor
- SYD985 + Niraparib
-
Antwerp, Belgium
- +5 more
Jan 23, 2023